Arbutus Biopharma Corp
Arbutus Biopharma Corp (ABUS): 12 pipeline candidates · 3 upcoming catalysts · ~54 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
54.1 months
D/E 0.07 · 0% dilution
Lead: Phase 3
12 candidates
3 upcoming, next in ~204d
N/A
A transparent, data-derived signal for Arbutus Biopharma Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$875.1M
Cash
$23.7M
Quarterly Burn
$8.1M
Runway
54.1 mo
Revenue
$179.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| AB-101 | Phase 1 |
| ab-729 | Phase 2 |
| aza-TdC | Phase 1 |
| Clofarabine | Phase 2 |
| Eribulin Mesylate | Phase 3 |
| imdusiran | Phase 2 |
| imdusiran (AB-729) | Phase 2 |
| Nucleoside Analogue | Phase 1 |
| Peg-IFNα-2a | Phase 2 |
| Sacituzumab Govitecan | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
168
Total value held
$571.7M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 25,891,480 | $116.5M |
| two seas capital lp | 18,557,543 | $83.5M |
| vanguard capital management llc | 13,377,822 | $60.2M |
| blackrock, inc. | 12,966,946 | $58.4M |
| state street corp | 6,342,510 | $28.5M |
| barclays plc | 4,316,095 | $19.4M |
| woodline partners lp | 4,020,344 | $18.1M |
| geode capital management, llc | 3,771,806 | $17.0M |
| adar1 capital management, llc | 3,133,175 | $14.1M |
| adage capital partners gp, l.l.c. | 2,664,941 | $12.0M |
Showing top 10 of 168 institutional holders of Arbutus Biopharma Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Arbutus Biopharma Corp's pipeline?
Arbutus Biopharma Corp (ABUS) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Arbutus Biopharma Corp's lead drug candidate?
Arbutus Biopharma Corp's most advanced tracked candidate is AB-101 (Phase 1) for Chronic Hepatitis b.
What is Arbutus Biopharma Corp's next catalyst?
Arbutus Biopharma Corp's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: HALAVEN" — expected January 8, 2027.
What is Arbutus Biopharma Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Arbutus Biopharma Corp has approximately 54.1 months of cash runway.
What is Arbutus Biopharma Corp's market capitalization?
Arbutus Biopharma Corp's market capitalization is approximately $875.1M.
Get the full picture on Arbutus Biopharma Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.